NEW YORK (GenomeWeb) – Cepheid said yesterday that it will delay the international market launch of its point-of-care platform, the Omni, by one year to the third quarter of 2017.

The firm's stock fell sharply on the news, down more than 19 percent on Nasdaq at mid-day trading following the announcement.

Cepheid first unveiled the Omni in July 2015, when it also announced plans to develop a line of more rapid tests, called Xpert Xpress.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.